Motility News

As we enter the fifth year of Healio Gastroenterology and Liver Disease, it is worth looking back at what made us stand out in 2018: the Peer Tested content from online and print as it fared throughout the year.

Healio Gastroenterology and Liver Disease reported live from Advances in IBD 2018 in Orlando, Florida, highlighting the latest research updates as well as interviews with leading researchers and clinicians. Miguel Regueiro, MD, chair of the Department of Gastroenterology, Hepatology and Nutrition at the Cleveland Clinic, speaks with fellows during a breakout session that highlighted life outside of training, including the legal aspects of an IBD practice. James Lindsay, PhD, BM BCh, FRCP, gives a keynote presentation with a European perspective on positioning biosimilars in IBD. Bruce and Cynthia Sherman announce the 2018 recipients of the Sherman Prize for their research in the treatment of Crohn’s disease and ulcerative colitis.

Approximately 50 million adults in the United States reported experiencing chronic pain in 2016 while 19.6 million U.S. adults reported experiencing high-impact chronic pain that resulted in a hindrance to at least one major life event, according to statistics from the CDC. These extreme numbers lead some experts to call this timeframe an era of chronic pain.

The American Gastroenterological Association released a clinical guideline on the management of opioid-induced constipation, informed by the most recent medical research and expert opinion.

Healio Gastroenterology and Liver Disease has compiled a list of the top five stories posted in December.

Patients who underwent supervised pelvic floor muscle training with biofeedback were five times more likely to experience improvements in fecal incontinence symptoms, according to research published in Clinical Gastroenterology and Hepatology.

Medtronic reported that the FDA approved the InterStim smart programmer, an app that assists patients in the long-term management of therapy for overactive bladder or chronic fecal incontinence.

The FDA has approved Motegrity for the treatment of adults with chronic idiopathic constipation, according to a company press release.

PHILADELPHIA — In this exclusive video from the American College of Gastroenterology Annual Meeting, Mike Nedham, product strategy lead for GI at Shire, discusses a survey the company conducted that he said revealed a need for more treatments for chronic idiopathic constipation.

PHILADELPHIA — In this exclusive video from the American College of Gastroenterology Annual Meeting, William Chey, MD, FACG, of the division of gastroenterology at the University of Michigan Health System, discusses a survey he conducted along with Shire Pharmaceuticals that explored the burden of illness related to chronic constipation.